Financhill
Back

Monte Rosa Therapeutics Vs. Sarepta Therapeutics Industry Stock Comparison

Buy
69

GLUE
Monte Rosa Therapeutics

Last Price:
8.90
Seasonality Move:
7.5%
Sell
49

SRPT
Sarepta Therapeutics

Last Price:
136.24
Seasonality Move:
14.88%
Buy
69
Monte Rosa Therapeutics (GLUE) is a Buy

Is Monte Rosa Therapeutics a Buy, Sell or Hold?

  • The current Monte Rosa Therapeutics [GLUE] share price is $8.60. The Score for GLUE is 69, which is 38% above its historic median score of 50, and infers lower risk than normal.
  • GLUE is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.
  • This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
49
Sarepta Therapeutics (SRPT) is a Sell

Is Sarepta Therapeutics a Buy, Sell or Hold?

  • The current Sarepta Therapeutics [SRPT] share price is $130.50. The Score for SRPT is 49, which is 2% below its historic median score of 50, and infers higher risk than normal.
  • SRPT is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
  • This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.

GLUE Stock Price Chart

What is Monte Rosa Therapeutics's stock price today?

  • The Monte Rosa Therapeutics share price today is $8.60
    Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and GLUE is experiencing slight buying pressure.

SRPT Stock Price Chart

What is Sarepta Therapeutics's stock price today?

  • The Sarepta Therapeutics share price today is $130.50
    Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and SRPT is experiencing buying pressure, which is a positive indicator for future bullish movement.

GLUE Technical Analysis

Chart Indicators Level Buy or Sell
MACD (12, 26): 0.41 Buy
Relative Strength Index (14 RSI): 57.05 Buy
Chaikin Money Flow: 142048 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (6.94 - 9.74) Buy
Bollinger Bands (100): (4.23 - 7.65) Buy

SRPT Technical Analysis

Chart Indicators Level Buy or Sell
MACD (12, 26): -2.3 Sell
Relative Strength Index (14 RSI): 64.59 Buy
Chaikin Money Flow: 3149400 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (111.02 - 128.88) Buy
Bollinger Bands (100): (119.18 - 142.3) Sell

GLUE Moving Averages

Moving Averages Level Buy or Sell
8-day SMA: 8.23 Buy
20-day SMA: 8.76 Sell
50-day SMA: 6.87 Buy
200-day SMA: 5.68 Buy
8-day EMA: 8.45 Buy
20-day EMA: 8.23 Buy
50-day EMA: 7.29 Buy
200-day EMA: 5.96 Buy

SRPT Moving Averages

Moving Averages Level Buy or Sell
8-day SMA: 112.07 Buy
20-day SMA: 117.27 Buy
50-day SMA: 121.92 Buy
200-day SMA: 129.99 Buy
8-day EMA: 116.28 Buy
20-day EMA: 117.14 Buy
50-day EMA: 121.91 Buy
200-day EMA: 125.98 Buy

Monte Rosa Therapeutics Earnings Growth & GLUE Earnings Dates

  • Analysts estimate an earnings increase this quarter of $0.08 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.44 per share, and a decrease next year of $0.60 per share.

Sarepta Therapeutics Earnings Growth & SRPT Earnings Dates

  • Analysts estimate an earnings increase this quarter of $2.87 per share, a decrease next quarter of $0.00 per share, an increase this year of $4.84 per share, and an increase next year of $8.76 per share.

Monte Rosa Therapeutics Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):

Sarepta Therapeutics Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):